Revolution Medicines (RVMD) Receivables - Other (2019 - 2020)
Revolution Medicines' (RVMD) quarterly Receivables - Other came in at $6.4 million in Q4 2020, down 26.83% year-on-year from $8.7 million in Q1 2020, and down 31.25% quarter-over-quarter from $9.3 million in Q3 2020.
Revolution Medicines (RVMD) Receivables - Other (2019 - 2020) Analysis & Trends
Revolution Medicines' Receivables - Other history runs 2 years deep, the most recent figure standing at $6.4 million for Q4 2020.
- On a quarterly basis, Receivables - Other fell 26.83% year-over-year to $6.4 million in Q4 2020; TTM through Dec 2020 was $6.4 million, a 26.83% decrease from a year earlier, with the FY2020 full-year figure at $6.4 million, down 26.83% from the prior year.
- Receivables - Other eased to $6.4 million in Q4 2020 per RVMD's latest filing, from $9.3 million in the prior quarter.
- Across five years, Receivables - Other topped out at $9.3 million in Q3 2020 and bottomed at $6.4 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 6.39 Mn |
| Dec 31, 2020 | 6.39 Mn |
| Sep 30, 2020 | 9.30 Mn |
| Sep 30, 2020 | 9.30 Mn |
| Jun 30, 2020 | 7.33 Mn |
| Jun 30, 2020 | 7.33 Mn |
| Mar 31, 2020 | 8.45 Mn |
| Mar 31, 2020 | 8.45 Mn |
| Dec 31, 2019 | 8.74 Mn |
| Dec 31, 2019 | 8.74 Mn |